A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

被引：0
|
作者：
Rugo, H.
Tolaney, S.
Dickler, M.
Kabos, P.
Ho, C-L
Wildiers, H.
Jerusalem, G.
Ales-Martinez, J. E.
Hossain, A.
Johnston, E.
Gianni, L.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[5] Tri Serv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan
[6] Univ Ziekenhuis Leuven Gasthuisbert, Leuven, Belgium
[7] Univ Sart Tilman, Ctr Hospitalier, Liege, Belgium
[8] Hosp Nuestra Senora Sonsoles, Complejo Hospitalario Avila Oncol, Avila, Spain
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] IRCCS Osped, Milan, Italy
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-OT2-01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-07
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).
    Wander, Seth Andrew
    Zangardi, Mark
    Niemierko, Andrzej
    Kambadakone, Avinash
    Kim, Leslie S. L.
    Xi, Jing
    Pandey, Apurva Kumari
    Spring, Laura
    Stein, Casey
    Juric, Dejan
    Kuter, Irene
    Moy, Beverly
    Mulvey, Therese Marie
    Vidula, Neelima
    Isakoff, Steven J.
    Yuen, Megan
    Brufsky, Adam
    Ma, Cynthia X.
    O'Shaughnessy, Joyce
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] COMPARISON BETWEEN EVEROLIMUS (AFINITOR®) AND CHEMOTHERAPY AGENTS (CAPECITABINE, DOCETAXEL AND DOXORUBICIN) FOR THE TREATMENT OF HORMONE RECEPTOR POSITIVE (HR+) HER2 NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER
    Vieira, J.
    Chandiwana, D.
    Taylor, M.
    Lewis, L.
    VALUE IN HEALTH, 2013, 16 (07) : A396 - A396
  • [23] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
    Alemany, Carlos
    Patel, Manish
    Mitri, Zahi
    Sparano, Joseph
    Borges, Virginia
    Makower, Della
    Klein, Pam
    Lawrence, Julia
    Le, Trinh
    Zujewski, Jo Anne
    Harmilton, Erika
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [25] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [26] Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
    Schmid, P.
    Cortes, J.
    Marme, F.
    Rugo, H. S.
    Tolaney, S. M.
    Oliveira, M.
    Loirat, D.
    Jhaveri, K.
    Yoon, O. K.
    Motwani, M.
    Wang, H.
    Delaney, R. J.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S635 - S636
  • [27] The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro, Matti
    De Laurentiis, Michelino
    Rea, Dan
    Bargallo Rocha, Juan Enrique
    Elizalde, Roberto
    Landherr, Laszlo
    Linderholm, Barbro
    Mamounas, Eleftherios
    Markopoulos, Christos
    Neven, Patrick
    Petrovsky, Alexander
    Rouzier, Roman
    Smit, Vincent
    Svedman, Christer
    Schneider, Daniel
    Thomssen, Christoph
    Martin, Miguel
    BREAST, 2017, 33 : 191 - 199
  • [28] Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer
    Wander, S. A.
    Spring, L. M.
    Stein, C. R.
    Yuen, M.
    Zangardi, M.
    O'Shaughnessy, J.
    Bardia, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)
    O'Shaughnessy, Joyce
    Johnston, Stephen
    Martin, Miguel
    Huober, Jens
    Toi, Masakazu
    Andre, Valerie AnneMarie
    Martin, Holly Rene
    Hardebeck, Molly Catherine
    Di Leo, Angelo
    Goetz, Matthew Philip
    CANCER RESEARCH, 2020, 80 (04)
  • [30] A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients
    Chan, Nancy
    Moore, Dirk
    Tandra, Pavankumar
    Rana, Jatin
    Omene, Coral
    George, Mridula
    Krishnamurthy, Jairam
    Desai, Shruti
    Patel, Nayana
    Wang, Yue
    Bicomong, Marc
    Tan, Xiao-Wei
    Hirshfield, Kim
    Ganesan, Shridar
    Toppmeyer, Deborah
    CANCER RESEARCH, 2022, 82 (04)
12345